Table 2.
Key studies linking lipid metabolic alterations to immune remodeling in CRC and metastases
| Study (PMID) | Model | Key lipid marker | Immune readout | Intervention | Evidence type |
|---|---|---|---|---|---|
| PMID: 28854168 | Mouse/Human CRC | CD36 | CD8⁺ T-cell exhaustion, Treg uptake | CD36 blockade | Causal (in vivo) |
| PMID: 33125861 | Human liver metastasis | FABP4, TREM2 macrophages | TAM immunosuppression, ICI resistance | None | Correlative (scRNA-seq) |
| PMID: 31217590 | Mouse CRC | Cholesterol | CD8⁺ T-cell exhaustion via ERS | Statin | Causal (in vivo) |
| PMID: 34715016 | Human CRC cohort | FASN | Treg/CD8 ratio, PD-L1 | FASN inhibitor | Correlative + preclinical |
| PMID: 30736843 | Human CRC/metastasis | Lysophosphatidylcholines | NK cell exclusion | None | Correlative (lipidomics) |